651 reports of this reaction
3.2% of all REMDESIVIR reports
#6 most reported adverse reaction
BRADYCARDIA is the #6 most commonly reported adverse reaction for REMDESIVIR, manufactured by Gilead Sciences, Inc.. There are 651 FDA adverse event reports linking REMDESIVIR to BRADYCARDIA. This represents approximately 3.2% of all 20,319 adverse event reports for this drug.
Patients taking REMDESIVIR who experience bradycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRADYCARDIA is moderately reported among REMDESIVIR users, representing a notable but not dominant share of adverse events.
In addition to bradycardia, the following adverse reactions have been reported for REMDESIVIR:
The following drugs have also been linked to bradycardia in FDA adverse event reports:
BRADYCARDIA has been reported as an adverse event in 651 FDA reports for REMDESIVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRADYCARDIA accounts for approximately 3.2% of all adverse event reports for REMDESIVIR, making it a notable side effect.
If you experience bradycardia while taking REMDESIVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.